CEBPA and acute myeloid leukemia: Another report stated that there was no significant correlation between both KRAS and NRAS mutation status in AML and other mutations such as CEBPA, FLT3, WT1, IDH1/2, or MLL, but KRAS was associated with mutated NPM1 [88].